A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.

McMeekin, D Scott

A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. [electronic resource] - Gynecologic oncology Nov 2012 - 356-61 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

1095-6859

10.1016/j.ygyno.2012.07.095 doi


Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors--therapeutic use
Angiogenic Proteins--blood
Biomarkers, Tumor--blood
Carcinosarcoma--blood
Drug Administration Schedule
Enzyme-Linked Immunosorbent Assay
Female
Humans
Middle Aged
Survival Analysis
Thalidomide--therapeutic use
Treatment Outcome
Uterine Neoplasms--blood